to be lowered to the same level as they are in similarly developed nationsa pricing philosophy that guides the other government initiatives, including its DTC program.
10.1093/ndt/gfad009 [DOI] [PMC free article] [PubMed] [Google Scholar] 39
SGLT2 inhibitors have proven efficacy in slowing chronic kidney disease progression, reducing albuminuria, and decreasing risk of end-stage renal disease
The strain-level question matters
Tirzepatide activates both GLP-1 and GIP receptors, whereas semaglutide targets GLP-1 alonea pharmacological distinction that affects washout periods, baseline dosing, and individual response variability
While they have similarities in their mechanisms of action and side effects, each medication has unique characteristics that set them apart